An interventional study of Transcutaneous Auricular Vagus Nerve Stimulation and Sham Transcutaneous Auricular Vagus Nerve Stimulation in Chronic Prostatitis, sponsored by Jiani Wu. Recruiting at 1 site in China. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Jiani Wu · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Prostatitis with a site in China — 2 open to participants now, 2 under way, none of them phase 3. Prostatitis · China.
Among the 13 studies in Prostatitis with a site in China, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 8 with no phase, and was the 12th registered.
89 studies on the registry are indexed under Prostatitis; 12 are open to participants now.
Browse Prostatitis studies →2 of the 13 studies in Prostatitis with a site in China are open now. Recruiting first, the newest first:
Shaanxi Provincial People's Hospital · Sites in China
Ages 18+ · Men only · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 6 Prostatitis studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 50 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 68 is above the median of 61 across 74 interventional studies indexed under Prostatitis.
Median enrollment 211 across the 12 interventional studies, 400 across the 1 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 8 most frequent:
Jiani Wu is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Jiani Wu has 1 study filed under Prostatitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Prostatitis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06287970Jiani WuTaVNS Improves the Symptoms of Patients With Moderate to Severe CP/CPPS | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Prostatitis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) for moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). This study is a prospective, randomized, controlled trial. A total of 68 patients with CP/CPPS will be recruited. After baseline assessment, the patients will be randomized into taVNS group (n = 34) and sham-taVNS group (n = 34). The intervention of two group will last for 4 weeks with a 8-week follow-up period after the treatment. The National Institutes of Health chronic Prostatitis Symptom Score index (NIH-CPSI), International Prostate Symptom Score Scale (IPSS), European quality of Life-5 Dimensions Questionnaire (EQ-5D), self-rating anxiety Scale (SAS) and self-rating depression scale (SDS) will be assessed. The adverse events during the whole study will be recorded detailedly.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilateral auricular points of Xin (CO15) and Shen (CO10) will be stimulated by electrical stimulation. A disperse-dense wave will be used with a frequency of 4Hz/20Hz, a pulse width of 0.2ms will be set, and the current intensity will be modulated by the tolerance of the patient. note: taVNS, transcutaneous auricular vagus nerve stimulation
Device: Transcutaneous Auricular Vagus Nerve Stimulation
Bilateral ear lobes will be stimulated by electrical stimulation. A disperse-dense wave will be used with a frequency of 4Hz/20Hz, a pulse width of 0.2ms and a current intensity of 0.1mA will be set. note: taVNS, transcutaneous auricular vagus nerve stimulation
Device: Sham Transcutaneous Auricular Vagus Nerve Stimulation
In the experimental group, bilateral auricular point Xin (CO15) and auricular point Shen (CO10) will be stimulated, on where the vagus nerves distributed.
In the control group, bilateral earlobes will be stimulated with no vagus nerve distribution.
Change from baseline in National Institute of Health Chronic Prostatitis Symptom Index(NIH-CPSI) total score at week 4
The NIH-CPSI scale scores range from 0 to 43, with higher scores indicating more severe symptoms. The NIH-CPSI total score will be recorded once a week during the treatment period.
Time frame: Baseline, week 4
Change from baseline in National Institute of Health Chronic Prostatitis Symptom Index(NIH-CPSI) total score at week 8 and week 12
The NIH-CPSI scale scores range from 0 to 43, with higher scores indicating more severe symptoms. The NIH-CPSI total score will be recorded once a week during the treatment and follow-up period
Time frame: Baseline, week 8 and 12
The changes from baseline of NIH-CPSI pain score, urinary score and quality of life score, respectively at week 4, 8 and 12
The NIH-CPSI scores range from 0 to 43. The NIH-CPSI has three subscores: pain scores , urinary scores , and quality of life scores. The subscore of pain ranged from 0 to 21. The subscores of urination symptoms ranged from 0 to 10. The subscore of the effect of symptoms on quality of life ranges from 0 to 12. The higher the score, the more severe the symptoms. These subitem scores are specific to the symptoms of CP/CPPS and do not require other separate outcome measures. Each part of the NIH-CPSI score will be recorded weekly during the treatment and follow-up periods
Time frame: Baseline, week 4, 8 and 12
Proportion of responders at week 4, 8 and 12
Responder is defined as the patient with a decrease of ≥6 points in the NIH-CPSI total score compared with baseline. The proportion of responders will be calculated for each evaluation time point.
Time frame: Baseline, week 4, 8 and 12
The change from baseline in International Prostate Symptom Score (IPSS) score at week 4, 8 and 12
The IPSS scale scores range from 0 to 35, with higher scores indicating more severe symptoms. The total IPSS score will be recorded once a week during the treatment and follow-up period
Time frame: Baseline, week 4, 8 and 12
The change from baseline in EuroQol Five Dimensions Questionnaire (EQ-5D) at week 4, 8 and 12
The EQ-5D is mainly composed of two parts, the Descriptive System and the Visual Analogue Scale (VAS) . The description system of EQ-5D can generate a five-digit health status, which can be intuitively reflected in the five health dimensions. This health status can be converted into a single summary number (utility index value) according to the characteristics of the general population in a country/region, which can be used to reflect the health status. The Visual Analogue Scale (VAS) contains a vertical scale ranging from 0 to 100 to record the self-rated health status of the participants. The Visual Analogue Scale provides a quantitative description of respondents' perceptions of their overall health. The EQ-5D total score will be recorded once a week during the treatment and follow-up period
Time frame: Baseline, week 4, 8 and 12
The change from baseline in Self-rating Anxiety Scale (SAS) at week 4, 8 and 12
The standard score of the test result is obtained by summing the scores of the 20 items in the SAS scale, multiplying the resulting result by 1.25 and rounding to integer numbers. The cut-off value of the standard score is 53 points, with 53 to 62 points as mild depression, 63 to 72 points as moderate depression, and more than 73 points as severe depression. The total score of SAS will be recorded once a week during the treatment and follow-up period
Time frame: Baseline, week 4, 8 and 12
The change from baseline in the Self-rating Depression Scale (SDS) at week 4, 8 and 12
The standard score of the test result is obtained by summing the scores of the 20 items in the SDS scale, multiplying the resulting result by 1.25 and rounding to integer numbers. The cut-off value of the standard score is 53 points, with 53 to 62 points as mild depression, 63 to 72 points as moderate depression, and more than 73 points as severe depression. The total score of SDS will be recorded once a week during the treatment and follow-up period
Time frame: Baseline, week 4, 8 and 12
Evaluation of patient expectations
Patients will be asked before the randomization: ① Do you think transcutaneous vagal nerve stimulation will be effective? ② Do you think transcutaneous vagal nerve stimulation will help improve your symptoms of chronic prostatitis/chronic pelvic floor pain syndrome?
Time frame: Baseline before the randomization
Blinding Evaluation
Let the patient choose whether or not he or she has received the taVNS treatment after the treatment
Time frame: at the end of week 4
Incidence of Treatment-Emergent Adverse Events
Treatment-related adverse events will be recorded and evaluated between two groups
Time frame: The 4-week treatment period
Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in this article and any future publications from this study will be shared. This includes, but is not limited to: demographic information, clinical assessments, scores from the National Institutes of Health Chronic Prostatitis Symptom Score Index (NIH-CPSI), the International Prostate Symptom Score Scale (IPSS), the European Quality of Life Five-Dimensions Questionnaire (EQ-5D-5L), the Self-rating Anxiety Scale (SAS), and the Self-rating Depression Scale (SDS).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: IPD will be available starting 6 months after publication of the primary results and will remain accessible for at least 5 years.
Access criteria: De-identified data will be made available to qualified researchers upon reasonable request. Researchers must submit a methodologically sound research proposal to the corresponding author at jiani_wu@aliyun.com. Access to the data will be granted after the requester signs a formal data access agreement.
Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.
Of 21 interventional studies with no phase under Prostatitis, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's planned 33 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jiani Wu